Staging and risk assessment
. The most commonly used staging system is the Durie -Salmon classification (Table 1) . Patients should have a least a complete blood count, serum and urine protein electrophoresis, measurement of calcium, full skeleton X-ray survey and evaluation of renal function. . If available, MRI and/or PET scan may help distinguish between MGUS, smoldering and overt myeloma, and refine the Durie-Salmon classification as described in Table 2 . . A number of biological parameters are of prognostic importance (b 2 -microglobulin, C-reactive protein, LDH, serum albumin). The level of b 2 -microglobulin is most commonly used. Combining it with serum albumin has lead to a new International Prognostic Index, as described in Table 3 .
. If available, cytogenetics reveals additional prognostic information.
Treatment plan
. 
Treatment of relapses
. For relapses occurring after unmaintained remission, regimens similar to those used initially can induce a second remission. VAD is the standard option for patients who fail 
Response evaluation
. Assessment of response is based on the evaluation of serum and urine M-component by electrophoresis. Partial remission is defined by at least 50% reduction in serum M-component and at least 90% reduction in 24 h urine M-component. In patients with no M-component in serum and urine, complete remission assessment requires bone marrow aspiration (<5% plasma cells) and immunofixation.
Follow-up
. Full blood count, serum and urine electrophoresis or/and free light chain determination in serum or urine, creatinine, calcium, and b 2 -microglobulin should be done. 
